Syndromic testing

Tackle respiratory infections year-round

Meet the challenges that this respiratory season will bring

As COVID-19 public health measures are reduced, influenza-like illnesses (ILIs) and COVID-19 will converge this respiratory season. Similar symptomology between these pathogens and SARS-CoV-2, rising cases and the high risk of co-infections will likely present exceptional challenges to healthcare systems (1–3).

Diagnostic approaches using rapid molecular testing may help alleviate this burden (4,5). Highly multiplexed testing, commonly known as syndromic testing, can detect and differentiate >20 bacterial and viral pathogens in around one hour.

PHC, personalized healthcare, doctor, scientist, oncologist, pathologist, clinical, laboratory, discussing patient care, (Person/s, Scientist/s, Photography, MDx, Doctor/Physician, Personalized health care (PHC), Hospital)

Multiplex panels can make your job easier

As cases of influenza-like illness spike this respiratory season, you and your team will be under enormous pressure. Take the stress out of diagnostics and get patients back to their families sooner with a diagnostic tool that tests for multiple circulating respiratory pathogens at once. Learn how multiplex PCR panels can save you time, improve patient outcomes and benefit your hospital as a whole. 

Tackle antimicrobial resistance

Antimicrobial resistance (AMR) threatens the efficacy of our antimicrobials and increases the risk of common respiratory infections progressing to sepsis. Lower respiratory infections associated with AMR resulted in 1.5 million deaths in 2019 (1). But you can fight back against AMR. By rapidly and accurately diagnosing respiratory infections early, you can support evidence-based antimicrobial use. Join us this World Antimicrobial Awareness Week to help spread awareness and take control in the fight against AMR.

QIAstat-Dx, woman, physician, child, woman, mother, mom, asian, pharmacist, infectious disease, syndromic testing

Adopting a syndromic diagnostic approach to serve the community during COVID-19

When COVID-19 struck in Northwest Indiana, USA, CEO and president of Great Lakes Labs, Michelle Volk, knew that she wanted to help. She placed her trust in the QIAstat-Dx system to test for a wide range of pathogens, not just SARS-CoV-2, to help provide fast answers and peace of mind to her community.

The symptoms of flu, COVID-19 and other respiratory infections are all very similar, making them difficult to diagnose. Sensitive multiplex PCR panel testing is a fast and simple way to accurately diagnose your patients when multiple respiratory pathogens are circulating. In fact, the CDC and the Academy of Medical Sciences “strongly support multiplex testing” in this situation (2, 3).

With the QIAstat-Dx Respiratory SARS-CoV-2 Panel, you don’t just get results for 23 respiratory pathogens in about an hour. You also get access to Ct values and amplification curves, powerful connectivity features and on-demand epidemiology reports.

Learn more about the QIAstat-Dx Respiratory SARS-CoV-2 Panel
* Enterovirus and Rhinovirus are both detected, but not differentiated, with the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Learn more about the QIAstat-Dx Respiratory SARS-CoV-2 Panel

To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge detects and differentiates* 22 respiratory targets, including SARS-CoV-2 from nasopharyngeal swabs (NPS) eluted in universal transport media (UTM).

Ready to learn how syndromic testing with QIAstat-Dx can benefit your institution?
*Some features require a QIAstat-Dx Connectivity plan; flexible plans are available to meet your lab’s needs 

References
  1. Hodjat, P., Christensen, P.A., Subedi, S., Bernard, D.W., Olsen, R.J. and Long, S.W. (2021) The rapid reemergence of seasonal respiratory viruses in Houston, Texas, after relaxing COVID-19 restrictions. medRxiv. doi: https://doi.org/10.1101/2021.05.27.21257940
  2. Centers for Disease Control and Prevention Weekly U.S. Influenza Surveillance Report https://www.cdc.gov/flu/weekly/index.htm
  3. Centers for Disease Control and Prevention Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States https://emergency.cdc.gov/han/2021/han00443.asp
  4. European Centre for Disease Prevention and Control COVID-19 testing strategies and objectives https://www.ecdc.europa.eu/sites/default/files/documents/TestingStrategy_Objective-Sept-2020.pdf
  5. Centers for Disease Control and Prevention Testing Guidance for Clinicians When SARS-CoV-2 and Influenza Viruses are Co-circulating https://www.cdc.gov/flu/professionals/diagnosis/testing-guidance-for-clinicians-hospitaized.htm

The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory SARS-CoV-2 Panel are intended for in vitro diagnostic use.